Results 151 to 160 of about 26,546 (243)

Astrocytes as central integrators of neural circuit function: Mechanisms and dysregulation in neuropsychiatric disorders

Clinical and Translational Discovery, Volume 6, Issue 2, April 2026.
1. Astrocytes are central integrators of neural circuit function through tripartite synapse modulation and neurovascular coupling. 2. Dysregulation of glutamate/GABA homeostasis and neuroinflammation represents shared mechanisms across diverse neuropsychiatric disorders. 3.
Xinyu Liu, Xinyue Zhou, Ruotong Meng, Yanxi Chen, You Chen, Blake Highet, Maurice Curtis, Bernhard Hirt, Shunying Yu, Jin Zhou, Linya You   +10 more
wiley   +1 more source

“If We Don't Tell Our Stories, They'll Erase Us”: Understanding the Criminalization of Disabled Black American Activists

Diversity &Inclusion Research, Volume 3, Issue 2, April 2026.
ABSTRACT This qualitative phenomenological study explores the lived experiences of disabled Black American activists to examine how systemic criminalization intersects with race and disability. Guided by Black Disability Threat Theory (BDTT; Templeton 2024) and scholarship on the school‐to‐prison nexus, this research conceptualizes schools and activist
Da'Shay Templeton, Ta'lia Gordan, Ruslan Korchagin   +2 more
wiley   +1 more source

Axon Initial Segment: Structure, Biological Functions, Diseases, and Therapeutic Targets

MedComm, Volume 7, Issue 4, April 2026.
The axon initial segment (AIS) is a specialized axonal domain critical for maintaining neuronal polarity, action potential initiation, and network stability. This review summarizes the necessary elements for maintaining AIS structure and plasticity, discussing crucial biological functions of AIS in neuronal signaling and the neural circuit homeostasis,
Dong‐Yan Song, Lin Yuan, Weiguo Yang, Wen Li, Jia‐Yi Li   +4 more
wiley   +1 more source

Defining the Patient Journey and Identifying Digital Health Solutions in Treatment-Resistant Schizophrenia. [PDF]

Actas Esp Psiquiatr
Grasa E, Forment A, Alonso-Solís A, Ramalho L, Roldán A, Pousa E, Aussó S, Berdun J, Genova Tesoro A, Escudero J, Corripio I.   +10 more
europepmc   +1 more source

Altered Brain Tissue Volumes With Valproate Treatment for Schizophrenia

Journal of the Royal Society of New Zealand, Volume 56, Issue 2, April 2026.
Schizophrenia is a debilitating psychiatric condition that affects ≈0.5% of the global population. Some people with schizophrenia do not respond to first‐line antipsychotics and are prescribed clozapine; this is termed treatment‐resistant schizophrenia (TRS).
Thomas Cawood, Olivia K. Harrison, Meghan McIlwain, Robert R. Kydd, Bruce R. Russell   +4 more
wiley   +1 more source

Lifetime Mixed Depression and Childhood Trauma in Individuals With Bipolar Disorders

Acta Psychiatrica Scandinavica, Volume 153, Issue 4, Page 290-300, April 2026.
ABSTRACT Background and Aims Mixed Depression (MxD), characterized by the co‐occurrence of depressive and excitatory symptoms, is a prevalent yet often underdiagnosed presentation in bipolar disorders (BD), with significant implications for prognosis and treatment. Childhood trauma is a key environmental risk factor associated with a more severe course
Francesca Bardi, Mario Pinto, Alessio Simonetti, Marco Di Nicola, Marianna Mazza, Giovanni Manfredi, Georgios D. Kotzalidis, Gabriele Sani, Delfina Janiri   +8 more
wiley   +1 more source

Evaluation of preclinical antipsychotic models used to support first‐in‐human clinical trials

British Journal of Pharmacology, Volume 183, Issue 7, Page 1364-1389, April 2026.
Abstract Schizophrenia is regarded as a complex and heterogeneous psychiatric disorder, characterised by diverse symptoms and comorbidities, which complicate both clinical management and drug development. Current pharmacological treatment, primarily based on dopamine D2 receptor antagonism or partial agonism, which has not markedly progressed since the
Thi Viet Ha Nguyen, Declan P. McKernan, John P. Kelly   +2 more
wiley   +1 more source

Exploring High-Dose Olanzapine for Psychosis in an Adolescent With Treatment-Resistant Schizophrenia. [PDF]

Cureus
Aggarwal S, Sahu SP, Shah P, Knobles MJ.
europepmc   +1 more source

Epigenetic mechanisms and therapeutic innovations in chronic pain‐associated neuropsychiatric co‐morbidities

British Journal of Pharmacology, Volume 183, Issue 7, Page 1313-1340, April 2026.
Abstract Chronic pain, marked by nociceptive sensitization and maladaptive neuroplasticity, affects 30% of the global population with escalating socioeconomic burdens. Epidemiological data show a 2‐3‐fold increase in neuropsychiatric co‐morbidities among individuals with chronic pain, where epigenetic dysregulation serves as a key mechanism linking ...
Kai Zhang, Sijia Zhu, Na Xing, Zhen Zhou, Jiayi Chen, Tianen Si, Mingrui Li, Lin Jia, Yousef Rastegar‐Kashkooli, Tom J. Wang, Wei Zhu, Jing Li, Chao Jiang, Junmin Wang, Moxin Wu, Xiaoping Yin, Weidong Zang, Jian Wang, Songxue Su   +18 more
wiley   +1 more source